RA disease impact in patients not treated with advanced therapies; survey findings from the National Rheumatoid Arthritis Society
by NRAS
Recently NICE published a Final Appraisal Document in respect of a new JAK inhibitor (filgotinib – Jyseleca) giving access to people with RA who have so called ‘moderate’ disease in addition to those with ‘severe’ disease. This is the first time NICE have broadened their eligibility criteria for access to advanced therapies and is warmly welcomed by NRAS. This comes at the same time as a paper published by the National Rheumatoid Arthritis Society (P.…
Read more of this article

by Debbie Wilson, NRAS

The incidence of MSK conditions, particularly neck and shoulder pain, has gone up during the pandemic. This represents a significant amount of pain that would not have happened without the pandemic changing the way we live and work. Which got me wondering how much of the pre-pandemic MSK conditions would have been preventable.
At the first meeting in June, they decided to name themselves the “Young Voices” to reflect their role in raising awareness of the issues affecting young people living with these chronic conditions. …
NRAS is very excited to announce their brand new website has gone live. A lot of work has gone into development, implementation and design, ensuring an improvement in how NRAS provides information to their members, supporters and the wider rheumatoid arthritis (RA) community.
The Faculty of Sport and Exercise Medicine (UK) has published a statement on the role SEM consultants can play in new NHS long Covid rehabilitation clinics being set up in England.